(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.
Kazia Therapeutics's earnings in 2025 is -$13,442,857.On average, 4 Wall Street analysts forecast KZIA's earnings for 2026 to be -$970,088,353, with the lowest KZIA earnings forecast at -$1,070,860,985, and the highest KZIA earnings forecast at -$849,889,671. On average, 4 Wall Street analysts forecast KZIA's earnings for 2027 to be -$458,211,945, with the lowest KZIA earnings forecast at -$880,485,699, and the highest KZIA earnings forecast at $0.
In 2028, KZIA is forecast to generate -$433,443,732 in earnings, with the lowest earnings forecast at -$832,891,877 and the highest earnings forecast at $0.